Health
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new patient-reported outcomes data from the pivotal TRUST-II study of IBTROZI® (taletrectinib) in patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The new data will be presented on Sunday, May 31 at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026.
About this update from Nuvation Bio Inc.
[{"type":"text","content":"88% of TRUST-II patients reported improved or stable quality of life at first assessment, with the majority sustaining that benefit throughout treatment","length":152,"tagName":"p","attribs":{}},{"type":"text","content":"Cognitive function scores improved or remained stable throughout the course of treatment with IBTROZI","length":101,"tagName":"p","attribs":{}},{"type":"text","content":"IBTROZI provided rapid relief from burdensome symptoms, including cough and shortness of breath","length":95,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new patient-reported outcomes data from the pivotal TRUST-II study of IBTROZI® (taletrectinib) in patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The new data will be presented on Sunday, May 31 at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026.","length":486,"tagName":"p"},{"type":"image","alt":"Nuvation Bio logo (PRNewsfoto/Nuvation Bio Inc.)","displaySize":"","headline":null,"caption":"Nuvation Bio logo (PRNewsfoto/Nuvation Bio Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":67,"url":"https://media.zenfs.com/en/prnewswire.com/eb40545e5f1eb1361b80045a4fef7988"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VSdvqELO80DAUOQ0oaqyVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTExOA--/https://media.zenfs.com/en/prnewswire.com/eb40545e5f1eb1361b80045a4fef7988","width":400,"height":67},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/yIsvDmruq_yhMGxx8CU29w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTEwNw--/https://media.zenfs.com/en/prnewswire.com/eb40545e5f1eb1361b80045a4fef7988","width":400,"height":67}},"href":"https://mma.prnewswire.com/media/2924210/Nuvation_Bio_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""When considering treatment options for these patients, our primary clinical objective is to delay disease progression while simultaneously alleviating symptom burden and ensuring long-term tolerability," said presenting author, Yasir Elamin, M.D., Associate Professor of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. "Th...